Fig. 2: The H10ssF vaccine elicited mild reactogenicity. | npj Vaccines

Fig. 2: The H10ssF vaccine elicited mild reactogenicity.

From: Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine

Fig. 2

Percentage of participants (x-axis) reporting solicited reactogenicity symptoms (y-axis) in the seven days following each vaccination. For symptoms persisting more than 1 day, a single count per person at the maximum severity of the symptom was plotted. No injection site redness, pruritus, bruising, or fevers were reported. N/A indicates that no second vaccination was administered to the dose group.

Back to article page